Autopsy report · NCT03394196
RESIST-2: 2nd-line ART for HIV-2 Infection
Cause of deathStaffing, sites or logistics, also funding or business
“COVID-19 and Funding”
Life of this trial
- Registered 7 months before it started.
- Ran for about 1 year 11 months before it stopped.
- 152 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Conditions
- HIV-2 Infection
- Interventions
- HIV-2 Genotypic Drug Resistance Testing using DBS; 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID); 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ); 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)
- Participants
- 152
- Sites
- 2
- Countries
- Senegal
Trials that died the same way
- High Risk Outpatient Intern-led Care (HeROIC) Clinic Initiative
“Covid-19, funding” - Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device
“Lack of funding/Covid-19” - Research on Translational Outcomes of Alcohol (Project RETRO)
“COVID-19 and expiration of funding” - A Mind-Body Intervention for Chemotherapy-Induced Peripheral Neuropathy
“COVID-19 pandemic” - Vitamin C to Reduce Vasopressor Dose in Septic Shock
“COVID 19”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.